SG Americas Securities LLC Lowers Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

SG Americas Securities LLC trimmed its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 44.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,343 shares of the company’s stock after selling 39,982 shares during the quarter. SG Americas Securities LLC’s holdings in Recursion Pharmaceuticals were worth $334,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Allspring Global Investments Holdings LLC purchased a new position in shares of Recursion Pharmaceuticals in the 3rd quarter worth approximately $25,000. Decker Retirement Planning Inc. acquired a new stake in Recursion Pharmaceuticals in the fourth quarter valued at approximately $26,000. GAMMA Investing LLC grew its holdings in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after purchasing an additional 4,091 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after purchasing an additional 3,377 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on RXRX shares. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. KeyCorp cut their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This represents a 0.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total value of $87,455.08. Following the sale, the director now owns 7,066,113 shares in the company, valued at $53,985,103.32. This trade represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX opened at $7.61 on Wednesday. The firm has a market capitalization of $2.97 billion, a P/E ratio of -4.97 and a beta of 0.86. The stock has a 50-day simple moving average of $7.09 and a two-hundred day simple moving average of $6.90. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $5.60 and a fifty-two week high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. During the same quarter in the prior year, the business posted ($0.43) earnings per share. The firm’s revenue was up 147.6% compared to the same quarter last year. On average, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.